Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/46228
Title: Correlation of cyclin D1, HER2, and AMACR expressions with histologic grade in bladder urothelial carcinomas
Authors: Karakaya, Yeliz Arman
Oral, Esin
Keywords: Alpha-methyl-CoA racemase
bladder cancer
cyclin D1
human epidermal growth factor receptor 2
Methylacyl-Coa Racemase
Transitional-Cell Carcinoma
Receptor 2 Expression
Trastuzumab
Cancer
Association
Multicenter
Gemcitabine
Paclitaxel
Cisplatin
Publisher: Wolters Kluwer Medknow Publications
Abstract: Background and Objective: Bladder cancer is the ninth most common type of cancer worldwide. We aimed to investigate the relationship between tumor grade, lamina propria invasion, muscularis propria invasion, and lymphovascular invasion and human epidermal growth factor receptor 2 (HER-2), cyclin D1, and alpha-methyl-CoA racemase (AMACR) expressions in bladder cancer. Materials and Methods: The study included patients who underwent complete TURBT. In total, 72 cases of bladder cancer diagnosed by two pathologists were selected. AMACR, HER-2, cyclin D1 expressions were detected immunohistochemically. Results: The study population comprised 80% (57) males and 20% (15) females (mean age, 68 years). Further, 35 cases were noninvasive and 37 invasive urothelial carcinoma and 38 patients had low-grade tumor and 34 high-grade tumor. Intense immunostaining was observed with cyclin D1 for 75% tumors, AMACR for 39%, and HER-2 for 86%. High expressions of cyclin D1 and AMACR were observed in high-grade tumors (P < 0.05 and P < 0.005, respectively). High expression of HER-2 (2 and 3 positive) was found both at low- and high-grade tumors (84% and 88%, respectively). Conclusion: Cyclin D1, AMACR expressions were found to be significant predictive factors of high-grade tumors. High Her-2 expression in patients with bladder carcinoma may indicate that they are potential targets for treatment. These markers may be important in determining prognosis of tumors and may be valuable for guiding treatment options.
URI: https://doi.org/10.4103/IJPM.IJPM_980_19
https://hdl.handle.net/11499/46228
ISSN: 0377-4929
0974-5130
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

3
checked on Dec 21, 2024

WEB OF SCIENCETM
Citations

3
checked on Dec 19, 2024

Page view(s)

38
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.